Phase 1 N=32 Safety and Tolerability of the Ophthalmic Gel PRO-165 Versus Artelac® Nightime Gel
Dry Eye Syndromes
Primary: Adverse Events — 3; 5 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=64 Lactobacillus Acidophilus and Postmenopausal Women
Bone Loss · Post Menopausal Osteoporosis · Mineralization
Primary: Calcium — 1.88; 2.04 mmol/L
N/A N=359 Perioperative Palliative Care Surrounding Cancer Surgery for Patients & Their Family Members
Gastrointestinal Cancer
Primary: Patient Quality of Life Patient Quality of Life 12 Weeks After Surgery — 138.54; 136.90 score on a scale — p=.623
Phase 2 N=75 Study of Bitopertin to Evaluate the Safety, Tolerability, Efficacy, and PPIX Concentrations in Participants With EPP
Erythropoietic Protoporphyria
Primary: Percent Change From Baseline in Whole Blood Metal-free PPIX Levels — 8.07; -21.48; -41.74 Percent Change
N/A N=200 Student Behavior in School Accident Precautions
Health Behavior
Primary: Behavior Towards The Security Precautions Against School Accidents — 134.46; 131.66; 136.68; 132.73 Scale score
Phase 4 N=30 Peripheral Nerve Blocks for Above-the-knee Amputations
Peripheral Vascular Diseases · Hyperglycaemia (Diabetic) · Hypertension
Primary: Peripheral Nerve Block Success as a Primary Anesthetic — 1 Participants
Phase 1 N=80 A Study to Test How Well Men Tolerate Different Doses of BI 3006337
Healthy
Primary: Number of Subjects With Drug-related Adverse Events (AEs) After a Single Dose of BI 3006337 — 0; 0; 1; 0 Participants
Phase 4 N=245 Evaluating the Dose Timing (Morning vs Evening) of Endocrine Therapy and Its Effects on Tolerability and Compliance
Breast Cancer
Primary: Change in Endocrine Toxicity and Tolerability at 12 Weeks — -2.2; -5.0 units on a scale
Phase 1 N=15 A Study in Healthy People to Compare 2 Different Formulations of Nerandomilast Tablets When Taken With or Without Food
Healthy
Primary: AUC0-tz (Area Under the Concentration-time Curve of Nerandomilast in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point) for Treatment T1 vs…
Phase 2 N=20 Personalized Immunotherapy in Patients With Recurrent /Metastatic SCCHN That Have Progressed on Prior Immunotherapy
Squamous Cell Carcinoma of the Head and Neck
Primary: Probability of Objective Response (OR) - Selected Treatment — 0 percentage of patients
N/A N=30 Observational Study on JuniOrtho Plating System for Deformities and Fractures Treatment in Lower Limb
Deformity · Defect, Congenital · Trauma
Primary: Percentage (%) of Subjects With at Least One Serious/Not Serious Adverse Event Certainly Related or Possibly Related to JPS (ADEs) — 3.3 percentage of subjects
N/A N=14 Multisensory Early Oral Administration of Human Milk in Preterm Infants
Infant Development · Stress
Primary: Feasibility of Intervention — 0; 7 Participants
N/A N=17 Altitudes: A Digital Intervention to Support Caregivers
Care Burden · Care Giving Burden · Caregiver Burnout
Primary: Mean Change in Altitudes Health Care Climate Questionnaire (A-HCCQ) - Total Score — 0.091 Scores on a scale
N/A N=25 MRI- Guided Transurethral Ultrasound Ablation of Localized Prostate Cancer
MRI Guided Transurethral Ultrasound Ablation · Localized Prostate Cancer · Ablation Therapy
Primary: Absence of Clinically Significant Cancer (CSC) on Control Biopsy at 1-year Follow-up. — 8 Participants
N/A N=20 Accommodative Behaviors in Multifocal Contact Lenses
Accommodation Disorder
Primary: Objective Accommodative Response (in Diopters) on the Grand Seiko Autorefractor at 2.5 Diopters (40 cm) — 1.20; 1.03 Diopters